H22 for Habits
What You Need to Know Before You Apply
What is the purpose of this trial?
H22 - Unconscious Mind Training and Memory Encoding
Phase I
The core problem this clinical trial, H22, seeks to address is the pervasive challenge of modifying deeply ingrained, often unconscious, unwanted behaviors within the general population. Many individuals struggle with habits or actions that negatively impact quality of life, productivity, or well-being, yet conventional methods often fall short due to the unconscious nature of these behaviors.
Specifically, the trial aims to investigate the efficacy of H22, a novel intervention designed to engage and train the unconscious mind, in mitigating these unwanted behaviors. The central hypothesis guiding this research is that H22 training will empower volunteers to significantly reduce the frequency and intensity of identified unwanted behaviors.
Who Is on the Research Team?
Matthew Quitto II
Principal Investigator
Dream Video LLC
Are You a Good Fit for This Trial?
This trial is for adults who can read and write, and are willing to follow the study instructions. It's aimed at people wanting help with unwanted habits or behaviors that affect their daily life.Inclusion Criteria
Exclusion Criteria
What Are the Treatments Tested in This Trial?
Interventions
- H22
Trial Overview
The study is testing H22, a new training method designed to work with the unconscious mind to help reduce unwanted behaviors. This is an early-phase (Phase I) trial focused on safety and initial effectiveness.
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
H22 interventions are administered once daily over a period of fourteen days.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Dream Video LLC
Lead Sponsor
Dream Holdings Research
Collaborator
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.